Woman working with reports and charts over wooden office desk. Top view

Clearside Biomedical, Inc. [NASDAQ:CLSD]: Analyst Rating and Earnings

Stock market traders oftentimes pay a lot of attention to what top analysts say regarding a potential investment. Regarding Clearside Biomedical, Inc. [CLSD], the latest average analyst recommendation we can see is from the quarter closing in December. On average, stock market experts give CLSD an Outperform rating. Its stock price has been found in the range of 37.97 to 49.92. This is compared to its latest closing price of $1.41.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Clearside Biomedical, Inc. [CLSD] is sitting at 2.25. This is compared to 1 month ago, when its average rating was 2.25.

Pay attention for this company’s financial results, of which the next release is scheduled to happen on Wed 13 Mar (In 29 Days).

Fundamental Analysis of Clearside Biomedical, Inc. [CLSD]

Now let’s turn to look at profitability: with a current Operating Margin for Clearside Biomedical, Inc. [CLSD] sitting at -16929.86.

This company’s Return on Total Capital is -107.50, and its Return on Invested Capital has reached -198.70%. Its Return on Equity is -126.73, and its Return on Assets is -94.13. These metrics suggest that this Clearside Biomedical, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Clearside Biomedical, Inc. [CLSD] has generated a Total Debt to Total Equity ratio of 37.40. Similarly, its Total Debt to Total Capital is 27.22, while its Total Debt to Total Assets stands at 19.78. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 22.46, and its Long-Term Debt to Total Capital is 16.34. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -0.24. The Enterprise Value to Sales for this firm is now 253.12, and its Total Debt to Enterprise Value stands at 0.05. Clearside Biomedical, Inc. [CLSD] has a Price to Book Ratio of 8.29.

Shifting the focus to workforce efficiency, Clearside Biomedical, Inc. [CLSD] earns $10,147 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.90 and its Current Ratio is 2.90. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Performance Indicators

Let’s now turn our attention to trading performance: Clearside Biomedical, Inc. [CLSD] has 28.97M shares outstanding, amounting to a total market cap of $40.85M. Its stock price has been found in the range of 0.99 to 15.33. At its current price, it has moved by -91.00% from its 52-week high, and it has moved 39.39% from its 52-week low.

This stock’s Beta value is currently , which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 63.43. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Clearside Biomedical, Inc. [CLSD] a Reliable Buy?

Clearside Biomedical, Inc. [CLSD] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.